Company Sponsored Symposia
Sunday, 18 June 2017
| Company Sponsored Symposium (CSS 1) Thermo Fisher Scientific Hall 1, 10:30 - 12:00 |
 |
The story of IgE – The next 50 years
Chair: SGO Johansson, Sweden
The molecular allergology revolution – Components and microarrays in prediction of allergic diseases
Marianne van Hage, Sweden
IgE and IgG4 antibodies to specific proteins in allergy, asthma and eosinophilic esophagitis
Thomas Platts-Mills, United States
Food allergy-induced anaphylaxis – allergen components and cofactors
Victoria Cardona, Spain
Diagnostic tools in insect venom allergy - State of the art and future directions
Thilo Jakob, Germany
| Company Sponsored Symposium (CSS 2) Novartis Pharma AG Hall 3a, 13:30 – 15:00 |
 |
As if severe allergic asthma wasn´t enough: associated and treatment-induced comorbidities 
Chair: Jean Bousquet, France
Welcome and introduction
Jean Bousquet, France
Pathological mechanisms of allergy in asthma and comorbidities: a central role for IgE
Oscar Palomares, Spain
Uncovering nasal polyps, where are we?
Claus Bachert, Sweden
Navigating corticosteroid-induced comorbidities in patients with SAA
Matthias Blüher, Germany
Re-addressing SAA treatment: summarizing the omalizumab evidence in children and adults
Nikos Papadopolous, United Kingdom
| Company Sponsored Symposium (CSS 3) STALLERGENES GREER Room 101, 15:30 – 17:00 |
 |
Long term evidence of SLIT: do we have a breakthrough in 2017?
Chaired by Antonella Muraro, Italy & Thomas Casale, United States
Introduction: Long term evidence of SLIT
Antonella Muraro, Italy
Allergic sensitization and the atopic march: natural progression and long term SLIT targets
Paolo M. Matricardi, Germany
How far does the clinical trial evidence take us to prove SLIT’s long term effects?
Thomas Casale, United States
Finding the breakthrough in real world evidence?
Stefan Zielen, Germany & Ulrich Wahn, Germany
Conclusion: Do we have a breakthrough in 2017?
Thomas Casale, United States
Monday, 19 June 2017
| Company Sponsored Symposium (CSS 4) Mylan Hall 5a, 10:45 – 12:15 |
 |
The allergic rhinitis challenge: perception, control and real-life effectiveness
Chairman’s Introduction
Erkka Valovirta, Finland
Changing the perception of the AR problem: barriers and solutions
Mike Bewick, United Kingdom
A simplified way to manage AR: do you agree with the experts?
Jean Bousquet, France
AR control in real life: the next battle field
Magnus Wickman, Sweden
Discussion and wrap-up
All
| Company Sponsored Symposium (CSS 5) HAL Allergy Hall 3a, 13:45 – 15:15 |
 |
Roadmap of Innovative and Registered Allergen Immunotherapy
Chairs: Oliver Pfaar, Germany
Dirk-Jan Opstelten, The Netherlands
Introduction – Insights to AIT Clinical Study Program
Dirk-Jan Opstelten, The Netherlands
The TAV Program – Implications for the Allergologist in Europe
Ludger Klimek, Germany
Grass allergen immunotherapy – Where we are
Moisés Calderón, United Kingdom
Birch or Trees – From Allergen Source to Immunological Active Compounds
Krzysztof Kowal, Poland
Clinical Development of Immunotherapy for Peanut Allergy
Carsten Bindslev-Jensen, Denmark
| Company Sponsored Symposium (CSS 6) Uriach Hall 3d, 15:45 – 17:15 |
 |
Consolidated strategies in the management of allergies
Chairs’ welcome and introduction
Torsten Zuberbier, Germany
Marek L. Kowalski, Poland
Lectures
What’s new in ARIA and Urticaria guidelines?
Torsten Zuberbier, Germany
The added value of Rupatadine in children
Paraskevi Xepapadaki, Greece
Rupatadine: a safe choice in the treatment of allergies
Joaquim Mullol, Spain
Discussion and concluding remarks
Moderated by Torsten Zuberbier, Germany and Marek L. Kowalski, Poland
Tuesday, 20 June 2017
| Company Sponsored Symposium (CSS 7) ALK Hall 5a, 10:30 – 12:00 |
 |
Step into the future of paediatric respiratory allergic disease
Chairs: Mika Mäkelä, Finland
Eckard Hamelmann, Germany
What can the HDM SLIT-tablet offer adolescents living with HDM allergic rhinitis?
Michael S Blaiss, United States
HDM allergic asthma - addressing the unmet needs in children and adolescents
Carmen Vidal, Spain
Benefits of early intervention to prevent asthma in children with hayfever
Graham Roberts, United Kingdom
| Company Sponsored Symposium (CSS 8) Allergopharma GmbH & Co. KG Hall 3g, 15:30 – 17:00 |
 |
FASIT (Future of the Allergists and Specific Immunotherapy) meets EAACI: Novel Patient Profiling, Promising Treatments and Regulatory Challenges
Chairs: Marek Jutel, Poland
Ulrich Wahn, Germany
New Promising Perspectives in AIT
Marek Jutel, Poland
Molecular Approaches for AIT - the Peril of Phase III Trials
Jörg Kleine-Tebbe, Germany
The Use of AIT in Europe - Regulatory Aspects and Call for Harmonization
Oliver Pfaar, Germany
How can we offer High Quality Diagnostics for our Patients in the Future?
Piotr Kuna, Poland